All In Biotech

Drug Trial Radar · NCT07240220

The Mother-Daughter Project: Merck-4

The Mother-Daughter Project: Inclusion of Difficult-to-reach Kenyan Families, and Studies of Factors Influencing the Immune Response to HPV Vaccination (Merck-4)

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

2,500

Planned (sponsor's estimate)

Start

Jul 22, 2026

Primary completion

Aug 1, 2028

Study completion Aug 1, 2028

Sponsor

Lead sponsor
Indiana UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
Female only, from 9 years, up to 49 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This project serves to continue a community-based initiative, known as the Kenya Mother-Daughter Cervical Cancer Eradication Project, or the Mother-Daughter Project (MDP), in the Webuye region of Western Kenya. The MDP project, since its initiation in 2018, has sought to develop a framework for the eradication of cervical cancer through effective screening of adult women and through the vaccination of female children. This project specifically aims to collect additional data on the ability for HR-HPV testing to detect premalignant lesions of the cervix, especially in HIV-infected women, to investigate and identify barriers leading to non-participation in previous MDP efforts, and to examine factors associated with the immune response to HPV vaccination among rural Kenyan girls.

Conditions

  • Cervical Dysplasia

Interventions

  • Gardasil-9Biological

    The 9 valent vaccine will be offfered to 2000 adolescent girls. The 9 valent vaccine will be offered to 2000 adolescent girls. The first vaccination dose will be administered at a community meeting, after parental consent has been obtained. The second vaccination dose will be administered at a subsequent community meeting, 6 to 12 months after the first dose.

  • High Risk HPV DNA TestingDiagnostic test

    Self-collected cervical swabs will be tested for high-risk HPV using the Roche Cobas Assay. This assay provides specific HPV 16 or 18 detection, as well as detection of any of 12 additional oncogenic types (HPV types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68).

  • Visual Inspection with acetic acid (VIA) and possible cervical biopsyProcedure

    Cervical screening in Kenya is usually done through pelvic examination and VIA. Cervical biopsy will additionally be performed for all HIV-infected women, and for HIV-uninfected women with abnormal VIA results.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Detection of CIN2/3Time frame: Baseline
  2. Local knowledge and attitudesTime frame: Baseline and after HPV vaccination of daughters is complete (assessed 2 weeks after second vaccine)
  3. Barriers to participationTime frame: During a one-time interview
  4. Factors that influence immunity to the HPV vaccineTime frame: 24 months after second HPV vaccine

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Moi University

    Eldoret, Kenya · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.